Literature DB >> 23382313

Association of nucleotide-binding oligomerization domain-like receptor 3 inflammasome and adverse clinical outcomes in patients with idiopathic dilated cardiomyopathy.

Beibei Luo1, Fan Wang, Bo Li, Zhe Dong, Xiaoman Liu, Cheng Zhang, Fengshuang An.   

Abstract

BACKGROUND: The nucleotide-binding oligomerization domain-like receptor 3 (NLRP3) inflammasome is a multiprotein complex consisting of NLRP3, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and caspase-1. In peripheral blood mononuclear cells (PBMCs), NLRP3 can activate interleukin-1β (IL-1β), important in the chronic inflammatory process of idiopathic dilated cardiomyopathy (IDCM). Therefore, the NLRP3 inflammasome in PBMCs may be involved in the pathogenesis of IDCM. We evaluated the association of circulating levels of NLRP3 inflammasome and cardiac function in patients with IDCM and 6-month rehospitalization.
METHODS: We enrolled 54 patients with IDCM and 20 healthy volunteers and analyzed left ventricle ejection fraction (LVEF), electrocardiography findings and circulating levels of NLRP3, ASC, caspase-1, IL-1β, N terminal-pro type B natriuretic peptide (NT-pro BNP) and blood values. Patients were followed up for 6 months.
RESULTS: On admission and discharge, the circulating levels of NLRP3, ASC, caspase-1 and IL-1β were higher in IDCM patients than healthy controls (all p<0.05). In patients, NLRP3 mRNA level was associated with LVEF, NT-pro BNP level and monocyte count (all p<0.05). LVEF at admission and mRNA levels of NLRP3 and IL-1β at discharge were independent risk factors of 6-month rehospitalization for patients. High NLRP3 mRNA level was associated with cumulative rehospitalization rate (p<0.05).
CONCLUSIONS: NLRP3 level in PBMCs may be associated with cardiac function and rehospitalization in IDCM patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23382313     DOI: 10.1515/cclm-2012-0600

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  10 in total

1.  The inflammasome in heart failure.

Authors:  Eleonora Mezzaroma; Antonio Abbate; Stefano Toldo
Journal:  Curr Opin Physiol       Date:  2020-10-07

Review 2.  Targeting the NLRP3 inflammasome in cardiovascular diseases.

Authors:  Stefano Toldo; Eleonora Mezzaroma; Leo F Buckley; Nicola Potere; Marcello Di Nisio; Giuseppe Biondi-Zoccai; Benjamin W Van Tassell; Antonio Abbate
Journal:  Pharmacol Ther       Date:  2021-12-11       Impact factor: 13.400

Review 3.  Role of cytokines and inflammation in heart function during health and disease.

Authors:  Monika Bartekova; Jana Radosinska; Marek Jelemensky; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

4.  NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model.

Authors:  Beibei Luo; Bo Li; Wenke Wang; Xiangjuan Liu; Yanfei Xia; Cheng Zhang; Mingxiang Zhang; Yun Zhang; Fengshuang An
Journal:  PLoS One       Date:  2014-08-19       Impact factor: 3.240

5.  Global metabolomic profiling of acute myocarditis caused by Trypanosoma cruzi infection.

Authors:  Núria Gironès; Sofía Carbajosa; Néstor A Guerrero; Cristina Poveda; Carlos Chillón-Marinas; Manuel Fresno
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

6.  Interleukin-1β levels predict long-term mortality and need for heart transplantation in ambulatory patients affected by idiopathic dilated cardiomyopathy.

Authors:  Aneta Aleksova; Antonio Paolo Beltrami; Cosimo Carriere; Giulia Barbati; Pierluigi Lesizza; Martina Perrieri-Montanino; Miriam Isola; Piero Gentile; Elisabetta Salvioni; Tarcisio Not; Piergiuseppe Agostoni; Gianfranco Sinagra
Journal:  Oncotarget       Date:  2017-04-11

7.  NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy.

Authors:  Cheng Zeng; Fengqi Duan; Jia Hu; Bin Luo; Binlong Huang; Xiaoying Lou; Xiuting Sun; Hongyu Li; Xuanhong Zhang; Shengli Yin; Hongmei Tan
Journal:  Redox Biol       Date:  2020-03-30       Impact factor: 11.799

Review 8.  NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases.

Authors:  Yucheng Wang; Xiaoxiao Liu; Hui Shi; Yong Yu; Ying Yu; Minghui Li; Ruizhen Chen
Journal:  Clin Transl Med       Date:  2020-04-09

Review 9.  NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases.

Authors:  Eleonora Mezzaroma; Antonio Abbate; Stefano Toldo
Journal:  Molecules       Date:  2021-02-12       Impact factor: 4.411

Review 10.  Functional Amyloid Signaling via the Inflammasome, Necrosome, and Signalosome: New Therapeutic Targets in Heart Failure.

Authors:  Traci L Parry; Jason H Melehani; Mark J Ranek; Monte S Willis
Journal:  Front Cardiovasc Med       Date:  2015-05-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.